Gapping up
In reaction to earnings/guidance:
- CXM +16.8%, EVGO +7.5%, NEOG +5.6%, ATAT +1.3%, MANU +1.1%
Other news:
- VIGL +6.8% (FDA has lifted the partial clinical hold on VGL101 - remains on track to report interim data from Phase 2 trial in the second half of 2023)
- TREE +6.2% (committed to a workforce reduction plan that is intended to reduce operating costs; the reduction plan includes the elimination of approximately 13% of the company's current workforce)
- AVXL +5.6% (reports preliminary 48-week open-label extension Parkinson's disease dementia ANAVEX2-73-PDD-EP-001 Phase 2 study data)
- STIX +4.8% (authorizes $5 mln additional repurchases)
- LICY +3.2% (Reports Operational and Financial Results for Two-Month Period Ended December 31)
- GPRE +3.1% (Chairman retiring)
- PACW +2.7% (joining S&P SmallCap 600)
- MPW +2.7% (agrees to sell Healthscope portfolio)
- WW +2.1% (Millennium Management discloses 5.1% stake)
- MSGE +2% (Board approves spin-off of traditional live entertainment business; Expected to be Completed April 20)
- WWW +1.5% (working to improve operating performance)
- SSYS +1.5% (confirms receipt of revised unsolicited acquisition proposal from Nano Dimension (NNDM) for $19.55 per share in cash)
- VLO +1.1% (awarded $906 mln contract)
- CR +1% (joining S&P MidCap 400)
- OMGA +1% (announced a clinical supply agreement with Roche (RHHBY) to evaluate OTX-2002)
Analyst comments:
- GMED +3% (upgraded to Buy from Hold at Canaccord Genuity)
- EQNR +1.8% (upgraded to Buy from Hold at Deutsche Bank)
- NBIX +1.5% (upgraded to Buy from Hold at Canaccord Genuity)
- AMT +1.1% (upgraded to Outperform from Market Perform at MoffettNathanson)
- CCI +0.8% (upgraded to Outperform from Market Perform at MoffettNathanson)